Evidence map›Paper›PMID 37069366›Full record

Observational studyBreast cancer (Tokyo, Japan)2023

Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry.

Shozo Ohsumi, Kenichi Watanabe, Naoto Kondo, Yoshimasa Kosaka, Takashi Ishikawa, Miyuki Kitahara, Shinichiro Kubo, Mari S Oba, Tetsuya Kimura, Atsushi Takita and 1 more

Open access · hybridAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Breast cancer (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 1 country.

Shozo OhsumiDepartment of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umemoto-machi, Matsuyama, Ehime, 791-0280, Japan. osumi.shozo.ur@mail.hosp.go.jp.
Kenichi WatanabeDepartment of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
Naoto KondoDepartment of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Yoshimasa KosakaDepartment of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Takashi IshikawaDepartment of Breast Oncology and Surgery, Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan.
Miyuki KitaharaDepartment of Breast Surgery, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Kasama, Ibaraki, Japan.
Shinichiro KuboDivision of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Fukuyama, Hiroshima, Japan.
Mari S ObaDepartment of Medical Statistics, Toho University, Ota-ku, Tokyo, Japan.
Tetsuya KimuraPrimary Medical Science Department, Daiichi Sankyo Co., Ltd., Chuo-ku, Tokyo, Japan.
Atsushi TakitaData Intelligence Department, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan.
Hirofumi MukaiDivision of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Daiichi-Sankyo (Japan) · JPFukuyama City Hospital · JPIbaraki Prefectural Central Hospital · JPKitasato University · JPNagoya City University · JPNational Cancer Center Hospital East · JPNational Hospital Organization Hokkaido Medical Center · JPShikoku Cancer Center · JPToho University · JPTokyo Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis subgroup analysis of the Cancer-VTE Registry, a nationwide, large-scale, multicenter observational study with a 1-year follow-up, assessed real-world data on venous thromboembolism (VTE) among Japanese patients with breast cancer.

methodsPatients with stage II-IV pretreatment breast cancer screened for VTE at enrollment were included. During the 1-year follow-up period, incidences of VTE, bleeding, and all-cause death, and background factors associated with VTE risk were examined.

resultsOf 9,630 patients in the Cancer-VTE Registry analysis set, 993 (10.3%) had breast cancer (973 [98.0%] did not have and 20 [2.0%] had VTE at baseline). The mean age was 58.4 years, 73.4% of patients had stage II cancer, and 94.8% had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0. Risk factors for VTE at baseline by univariable analysis were age ≥ 65 years, ECOG PS of 2, VTE history, and D-dimer > 1.2 μg/mL. During follow-up, the incidence of symptomatic VTE was 0.4%; incidental VTE requiring treatment, 0.1%; composite VTE (symptomatic VTE and incidental VTE requiring treatment), 0.5%; bleeding, 0.2%; cerebral infarction/transient ischemic attack/systemic embolic event, 0.2%; and all-cause death, 2.1%. One patient with symptomatic VTE developed pulmonary embolism (PE) and died. Incidences of VTE and all-cause death were higher in patients with VTE vs without VTE at baseline.

conclusionsIn Japanese patients with breast cancer, VTE screening before initiating cancer treatment revealed a 2.0% prevalence of VTE. During follow-up, one patient had a fatal outcome due to PE, but the incidences of VTE were low. CLINICAL

trial registrationUMIN000024942; UMIN Clinical Trials Registry: https://www.umin.ac.jp/ctr/ .

Indexed as

Breast NeoplasmsPulmonary EmbolismVenous ThromboembolismAgedEast Asian PeopleFemaleHemorrhageHumansMiddle AgedRegistriesRisk FactorsBreast cancerJapanVenous thromboembolism

Identifiers

PMID37069366
PMCPMC10284999
OpenAlexW4366204049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.